Treating myeloma in 2020

Professor Andrew Spencer, Australia | Friday 28 August | 12.00pm to 1.00pm

Professor Andrew Spencer is Head of the Malignant Haematology and Stem Cell Transplantation Service at The Alfred Hospital, Professor of Haematology at Monash University and Head of the Myeloma Research Group, all in Melbourne, Australia. He moved to The Alfred Hospital in 1999 where he established an independent translational research program and was appointed Head of Malignant Hematology and Stem Cell Transplantation Services in 2007, establishing a first-in-human and early phase haematology clinical research unit at the hospital in 2009, with currently over 100 open trials with >700 registered trial patients.

He has extensive experience in academic pharma pre-clinical and clinical collaborations in developmental therapeutics and the design and implementation of investigator-initiated trials in multiple myeloma. He has >210 peer reviewed publications with over 16,100 citations and holds 5 international patents in multiple myeloma therapeutics. Since 2015 he has been an invited speaker at 48 international meetings on genomics, therapeutics and disease monitoring in multiple myeloma.

He is an invited investigator of the International Myeloma Foundation (IMF) Black Swan Research Initiative to lead the liquid biopsy development programme. He serves on the scientific advisory boards of the IMF and the International Myeloma Working Group.

He Chairs the Myeloma and Related Diseases Registry (MRDR), the Asia pacific (APAC) MRDR and the associated M1000 liquid biopsy biobank. He established the Australasian Myeloma Research Consortium (AMaRC) in 2016 and sits on the steering committee for the global MM registry initiative INSIGHT.

Click here to return to the program.